IQVIA vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
World's largest CRO and healthcare data company; $15.2B FY2024 revenue; 1B+ patient records; powers pharma R&D and commercial analytics; benefits from GLP-1 and oncology pipeline boom.
About
IQVIA Holdings is the world's largest contract research organization (CRO) and leading provider of healthcare data and analytics, formed in 2016 through the $9 billion merger of IMS Health (healthcare information and technology services) and Quintiles Transnational Holdings (clinical research services), headquartered in Durham, North Carolina and trading on NYSE (IQV). The company generated approximately $15.2 billion in revenues for FY2024 under CEO Ari Bousbib, who led both legacy companies and has driven the combined entity to become an indispensable partner to pharmaceutical and biotechnology companies across the drug development lifecycle—from clinical trial design and execution through regulatory approval and commercial launch analytics.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.